Playing the Long Game: AVTX Unveils AVTX-010, a Long-Acting IL-1β mAb, For Potential Development in HS And Other Inflammatory Indications.

Research evidence excerpt

Playing the Long Game: AVTX Unveils AVTX-010, a Long-Acting IL-1β mAb, For Potential Development in HS And Other Inflammatory Indications.

tions as publicly traded companies. This can result in less publicly available information, potentially less transparency,

and fewer sources of information regarding the private enterprises discussed in these materials. The information containedRESEARCH in this document may differ from information a private company may subsequently make public or otherwise share with

investors. BTIG assumes no responsibility for any such discrepancies. The reader should not assume that any discussion of private

companies discussed in these materials is to be regarded as an express or implied acknowledgement or accedence to any research

expectation of any private company if it goes public.

For a complete list of BTIG Disclosures including public company-specific disclosures and explanation of BTIG LLC’s research

Ratings Definitions for public companies, please visit https://research.btig.com/disclosures.

Investors in securities products bear certain risks in conjunction with those investments. The value of, and income from, any

investments may vary because of changes in interest rates or foreign exchange rates, securities prices or market indexes,

operational or financial conditions of companies or other factors within or beyond the companies’ control. Recipient of the

research reports should be aware that investments in securities may pose significant risks due to the inherent uncertainty

associated with relying on forecasts of various factors that can affect the earnings, cash flow and overall valuation of a company.

Any investment in securities should be undertaken only upon consideration of issues relating to the recipient’s overall investment